The lancet oncology
-
The lancet oncology · Aug 2024
Randomized Controlled Trial Multicenter Study Comparative StudyPerioperative nivolumab versus observation in patients with renal cell carcinoma undergoing nephrectomy (PROSPER ECOG-ACRIN EA8143): an open-label, randomised, phase 3 study.
The standard of care for patients with intermediate-to-high risk renal cell carcinoma is partial or radical nephrectomy followed by surveillance. We aimed to investigate use of nivolumab before nephrectomy followed by adjuvant nivolumab in patients with high-risk renal cell carcinoma to determine recurrence-free survival compared with surgery only. ⋯ US National Institutes of Health National Cancer Institute and Bristol Myers Squibb.
-
The lancet oncology · Aug 2024
Multicenter StudyMulti-organ immune-related adverse events from immune checkpoint inhibitors and their downstream implications: a retrospective multicohort study.
Understanding co-occurrence patterns and prognostic implications of immune-related adverse events is crucial for immunotherapy management. However, previous studies have been limited by sample size and generalisability. In this study, we leveraged a multi-institutional cohort and a population-level database to investigate co-occurrence patterns of and survival outcomes after multi-organ immune-related adverse events among recipients of immune checkpoint inhibitors. ⋯ US National Institutes of Health.
-
The lancet oncology · Aug 2024
Multicenter StudyCeliac plexus radiosurgery for pain management in advanced cancer: a multicentre, single-arm, phase 2 trial.
Refractory upper abdominal pain or lower back pain (retroperitoneal pain syndrome) related to celiac plexus involvement characterises pancreatic and other upper gastrointestinal malignancies and is an unmet need. We hypothesised that ablative radiation delivered to the celiac plexus would decrease pain. ⋯ Gateway for Cancer Research and the Israel Cancer Association.
-
The lancet oncology · Aug 2024
Comparative StudyClinical benefit, reimbursement outcomes, and prices of FDA-approved cancer drugs reviewed through Project Orbis in the USA, Canada, England, and Scotland: a retrospective, comparative analysis.
Project Orbis is a global initiative that aims to streamline regulatory review processes across international regulators in the USA, Canada, Australia, UK, Israel, Brazil, Singapore, and Switzerland to bring promising cancer drugs to patients earlier. We explored the clinical benefit, time to regulatory approval and health technology assessment recommendations, reimbursement outcomes, and monthly treatment prices of cancer drugs reviewed through this initiative. ⋯ None.
-
The lancet oncology · Aug 2024
Risks of adverse obstetric outcomes among female survivors of adolescent and young adult cancer in England (TYACSS): a population-based, retrospective cohort study.
There are limited data on the risks of obstetric complications among survivors of adolescent and young adult cancer with most previous studies only reporting risks for all types of cancers combined. The aim of this study was to quantify deficits in birth rates and risks of obstetric complications for female survivors of 17 specific types of adolescent and young adult cancer. ⋯ Children with Cancer UK, The Brain Tumour Charity, and Academy of Medical Sciences.